Emerging treatments for narcolepsy and its related disorders

Expert Opinion on Emerging Drugs

Volumn 15, Issue 1, 2010, Pages 139-158

  Nishino, Seiji ^a   Okuro, Masashi ^a  

^a MSLS   (United States)

Author keywords

hydroxybutyrate; Amphetamine; Antidepressants; Cataplexy; Hypnogogic hallucinations; Modafinil; Narcolepsy; Sleep paralysis; Stimulants

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARMODAFINIL; ATOMOXETINE; CAFFEINE; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; FLUVOXAMINE; HYPNOTIC SEDATIVE AGENT; IMIPRAMINE; IMMUNOGLOBULIN; MAZINDOL; METHYLPHENIDATE; MILNACIPRAN; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; OREXIN A; OXYBATE SODIUM; PEMOLINE; PREDNISONE; PROTRIPTYLINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ANOREXIA; BEHAVIOR MODIFICATION; BLOOD PRESSURE; BLURRED VISION; CATAPLEXY; CELL TRANSPLANTATION; CONSTIPATION; CONVULSION; DAYTIME SOMNOLENCE; DROWSINESS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPNAGOGIC HALLUCINATION; IMMUNOMODULATION; IMPOTENCE; INSOMNIA; IRRITABILITY; LIVER TOXICITY; MOOD CHANGE; NARCOLEPSY; NAUSEA; NIGHT SLEEP; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PATHOPHYSIOLOGY; PLASMAPHERESIS; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SWEATING; TACHYCARDIA; TREMOR; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; CATAPLEXY; CELL TRANSPLANTATION; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUGS, INVESTIGATIONAL; GENE THERAPY; HALLUCINATIONS; HUMANS; IMMUNOLOGIC FACTORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROPEPTIDES; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP PARALYSIS; SODIUM OXYBATE; WAKEFULNESS;

EID: 77749283396     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210903559852     Document Type: Review

References (161)

1. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52(1):27-78
2. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007;369(9560):499-511
3. American Narcolepsy Association. Stimulant medication survey. The Eye Opener 1992:January 1-3
4. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30(12):1705-11
5. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98(3):365-76
6. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59(10):1553-62
7. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355(9197):39-40
8. ICSD-2, editor, ICSD-2-International classification of sleep disorders. Diagnostic and coding manual. American Academy of Sleep Medicine. 2nd edition. Westchester, Illinois; 2005
9. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications In the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005;9(4):269-310
10. Hublin C, Kaprio J, Partinene M, et al. The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort. Ann Neurol 1994;35:709-16
11. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998;50(Suppl 1):S16-22
12. Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999;22(6):757-65
13. Honda Y. Clinical features of narcolepsy: Japanese experience. In: Honda Y, Juji T, editors, HLA in Narcolepsy. Springer-Verlag, New York; 1988. p. 24-57
14. Gelb M, Guilleminault C, Kraemer H, et al. Stability of cataplexy over several months-information for the design of therapeutic trials. Sleep 1994;17:265-73
15. Nishino S, Ripley B, Mignot E, et al. CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res 2002;110(1):1-7
16. Walterfang M, Upjohn E, Velakoulis D. Is schizophrenia associated with narcolepsy? Cogn Behav Neurol 2005;18(2):113-8
17. Koffel E, Watson D. Unusual sleep experiences, dissociation, and schizotypy: evidence for a common domain. Clin Psychol Rev 2009;29(6):548-59
18. Hishikawa Y, Wakamatsu H, Furuya E, et al. Sleep satiation in narcoleptic patients. Electroencephalogr Clin Neurophysiol 1976;41:1-18
19. Broughton R, Dunham W, Newman J, et al. Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched control. Electroencephalogr Clin Neurophysiol 1988;70:473-81
20. Montplaisir J, Billard M, Takahashi S, et al. Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption. Biol Psychiatry 1978;13(1):78-89
21. Godbout R, Montplaisir J. Comparison of sleep parameters in narcoleptics with and without periodic movements of sleep. In: Koella WP, Ruther E, Schulz H, editors, Sleep '84. Fischer Verlag, Gustav; 1985. p. 380-2
22. Mosko SS, Shampain DS, Sassin JF. Nocturnal REM latency and sleep disturbance in narcolepsy. Sleep 1984;7:115-25
23. Mayer G, Pollmächer T, Meier-Ewert K, Schulz H. Zur Einschätzung des Behinderungsgrades bei Narkolepsie. Gesundh Wes 1993;55:337-42
24. Schenck CH, Mahowald MW. Motor dyscontrol in narcolepsy: Rapid-Eye-Movement (REM) sleep without atonia and REM sleep behavior disorder. Ann Neurol 1992;32(1):3-10
25. Chokroverty S. Sleep apnea in narcolepsy. Sleep 1986;9(1):250-3
26. Guilleminault C, Dement WC, Passouant P, et al. Spectrum Publications, New York; 1976
27. Honda Y, Doi Y, Ninomiya R, Ninomiya C. Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep 1986;9(1):254-9
28. Schuld A, Hebebrand J, Geller F, Pollmacher T. Increased body-mass index in patients with narcolepsy. Lancet 2000;355(9211):1274-5
29. Lammers GJ, Pijl H, Iestra J, et al. Spontaneous food choice in narcolepsy. Sleep 1996;19(1):75-6
30. Mayer G, Hellmann F, Leonhard E, Meier-Ewert K. Circadian temperature and activity rhythms in unmedicated narcoleptic patients. Pharmacol Biochem Behav 1997;58(2):395-402
31. Sachs C, Kaisjer L. Autonomic control of cardiovascular reflexes in narcolepsy. J Neurol Neurosurg Psychiatry 1980;43:535-9
32. Nishino S, Ripley B, Overeem S, et al. Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001;50:381-8
33. Broughton R, Ghanem Q, Hishikawa Y, et al. Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. Le J Can Sci Neurol 1981;8(4):299-303
34. Aldrich MS. Automobile accidents in patients with sleep disorders. Sleep 1989;12:487-94
35. Alaila SL. Life effects of narcolepsy: measures of negative impact, social support and psychological well-being. In: Goswanmi M, Pollak CP, Cohen FL, Thorpy MJ, Kavey NB, editors, Loss, grief and care: psychosocial aspects of narcolepsy. Haworth Press, New York; 1992. p. 1-22
36. Broughton R, Ghanem Q. The impact of compound narcolepsy on the life of the patient. In: Guilleminault C, WC D Passouant P, editors, Narcolepsy. Spectrum, New York; 1976. p. 201-20
37. Roth B, Nevsimalova S. Depression in narcolepsy and hypersomnia. Schweitz Arch Neurol Neurochir Psychiatry 1975;116:291-300
38. Rogers AE. Problems and coping strategies identified by narcoleptic patients. J Neurosurg Nursing 1984;16(6):326-34
39. Roehrs T, Zorick F, Wittig R, et al. Alerting effects of naps in patients with narcolepsy. Sleep 1986;9(1):194-9
40. Garma L, Marchand F. Non-pharmacological approaches to the treatment of narcolepsy. Sleep 1994;17:S97-S102
41. Nishino S. Modes of action of drugs related to narcolepsy: pharmacology of wake-promoting compounds and anticataplectics. In: Goswami M, Pandi-Perumal SR, Thorpy MJ, editors, Narcolepsy. Humana, Totowa; 2009. In press
42. Kuczenski R, Segal DS, Cho AK, Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 1995;15(2):1308-17
43. Snyder SH, Taylor KM, Coyle JT, Meyerhoff JL. The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs. Am J Psychiatry 1970;127(2):199-207
44. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep 1994;17(4):352-71
45. Mitler MM, Hajdukovic R. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 1991;14(3):218-20
46. Simpson LL. Blood pressure and heart rate responses produced by d-amphetamine: correlation with blood levels of drug. J Pharmacol Exp Ther 1978;205(2):366-73
47. Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst 1960;21:704-6
48. Parkes JD, Baraitser M, Marsden CD, Asselman P. Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neurol Scand 1975;52:337-53
49. Guilleminault C, Carskadon M, Dement WC. On the treatment of rapid eye movement narcolepsy. Arch Neurol 1974;30:90-3
50. Passouant P, Billiard M. The evolution of narcolepsy with age. In: Guilleminault C, Dement WC, Passouant P, editors. Narcolepsy. Spectrum publication, New York; 1976. p. 179-86
51. Rogers AE, Aldrich MS, Berrios AM, Rosenberg RS. Compliance with stimulant medications in patients with narcolepsy. Sleep 1997;20(1):28-33
52. Auger RR, Goodman SH, Silber MH, et al. Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. Sleep 2005;28(6):667-72
53. Gonzalez MA, Pentikis HS, Anderl N, et al. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 2002;40(4):175-84
54. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 1988;12(5):695-700
55. Besset A, Tafti M, Villemin E, Billiard M. The effects of modafinil (300mg) on sleep, sleepiness and arousal in narcoleptic patients. Neurophysiol Clin 1993;23(1):47-60
56. Boivin DB, Montplaisir J, Petit D, et al. Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol 1993;16(1):46-53
57. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000;54(5):1166-75
58. Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49(2):444-51
59. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999;39(1):30-40
60. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999;39(3):281-8
61. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003;42(2):123-37
62. Hermant JF, Rambert FA, Deuteil J. Lack of cardiovascular effects after administration of modafinil in conscious monkeys. French Association des Pharmacologistes Tours. Fundam Clin Pharmacol 1991:825
63. Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology 1996;126(4):286-92
64. Edgar DM, Seidel WF, Contreras P, et al. Modafinil promotes EEG wake without intensifying motor activity in the rat. Can J Physiol Pharmacol 1994;72(Suppl 1):362
65. Nishino S, Okuro M. Armodafinil for excessive daytime sleepiness. Drugs Today (Barc) 2008;44(6):395-414
66. Iijima S, Sugita Y, Teshima Y, Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep 1986;9(1 Pt 2):265-8
67. Nishino S, Mao J, Sampathkumaran R, et al. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998;1:49-61, Available from: http://www.sro.org/1998/Nishino/49/
68. Rye DB, Dihenia B, Bliwise DL. Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion. Depress Anxiety 1998;7(2):92-5
69. Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 2004;61(7-8):857-72
70. Rall TR. Central nervous system stimulants. In: Gilman AG, Goodman LS, Rall TW, Murad F, editors, The pharmacological basis of therapeutics. 7th edition. Pergamon Press, New York; 1985. p. 345-82
71. Kennedy JS, Leduc BW, Scavone JM, et al. Pharmacokinetics of intravenous caffeine: comparison of high-performance liquid chromatographic and gas chromatographic methods. J Chromatogr 1987;422:274-80
72. Benowitz NL, Jacob P III, Mayan H, Denaro C. Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther 1995;58(6):684-91
73. Okuro M, Fujiki N, Sokoloff P, Nishino S. Valuations of wake promoting effects of paraxanthine in orexin/ataxin-3 narcoleptic mice Sleep 2009;32(Suppl):A35
74. Guerreiro S, Toulorge D, Hirsch E, et al. Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Mol Pharmacol 2008;74(4):980-9
75. Huang ZL, Qu WM, Eguchi N, et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci 2005;8(7):858-9
76. Thorpy MJ, Snyder M, Aloe FS, et al. Short-term triazolam use improves nocturnal sleep of narcoleptics. Sleep 1992;15(3):212-16
77. Scrima L, Johnson FH, Thomas EG, Hiller EE. The effects of gamma-hydroxybutyrate (GHB) on multiple sleep latency test (MSLT) in narcolepsy patients; a long term study. Sleep Res 1990;19:288
78. Scrima L, Hartman PG, Johnson FH Jr, Hiller FC. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 1989;26(4):331-43
79. Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci 1979;6(1):1-6
80. Broughton R, Mamelak M. Gamma-hydroxybutyrate in the treatment of compound narcolepsy: a preliminary report. In: Guilleminault C, Dement WC, Passouant P, editors, Narcolepsy. Spectrum, New York; 1976. p. 59-67
81. Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992;156(4):380-4
82. Mack RB. Love potion number 8 1/2. Gamma-hydroxybutyrate poisoning. N C Med J 1993;54(5):232-3
83. Wong CG, Gibson KM, Snead OC III. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci 2004;25(1):29-34
84. Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend 2001;63(1):1-22
85. Group UXMS. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5(2):119-23
86. Group UXMS. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26(1):31-5
87. Group USXMS. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25(1):42-9
88. Group UXMS. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1(4):391-7
89. Zvosec DL, Smith SW, Hall BJ. Three deaths associated with use of Xyrem. Sleep Med 2009;10(4):490-3
90. Sansa G, Iranzo A, Santamaria J. Obstructive sleep apnea in narcolepsy. Sleep Med 2009;11:93-5
91. Feldman NT. Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing. Sleep Breath 2009; Jul 23
92. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. Ann Emerg Med 1998;31(6):723-8
93. Andriamampandry C, Taleb O, Viry S, et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). FASEB J 2003;17(12):1691-3
94. Baldessarini RJ. How do antidepressants work? In: Davis JM, Mass JW, editors, The affective disorders. American Psychiatric Press, Wachington, D.C.; 1983. p. 243-60
95. Langdon N, Shindler J, Parkes JD, Bandak S. Fluoxetine in the treatment of cataplexy. Sleep 1986;9(2):371-3
96. Montplaisir J, Godbout R. Serotoninergic reuptake mechanisms in the control of cataplexy. Sleep 1986;9(1 Pt 2):280-4
97. Schrader H, Kayed K, Bendixen Markset AC, Treidene HE. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand 1986;74(4):297-303
98. Mignot E, Renaud A, Nishino S, et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology 1993;113(1):76-82
99. Nishino S, Arrigoni J, Shelton J, et al. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep 1993;16(8):706-12
100. Takahashi S. The action of tricyclics (alone or in combination with methylphenidate) upon several symptoms of narcolepsy. In: Guilleminault C, Dement WC, Passouant P, editors, Narcolepsy. Spectrum Publication, New York; 1976. p. 625-38
101. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 1986;9(1 Pt 2):285-9
102. Nishino S, Arrigoni J, Shelton J, et al. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 1997;17:6401-8
103. Kotorii N, Okuro M, Takahashi T, et al. Effects of thyrotropin-releasing hormone analogs in the narcoleptic model mouse. Sleep 2009;32(Suppl). In press
104. Shiba T, Fujiki N, Wisor J, et al. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 2004;27(Suppl):A241-A2
105. Parmentier R, Anaclet C, Guhennec C, et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol 2007;73(8):1157-71
106. Okura M, Riehl J, Mignot E, Nishino S. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology 2000;23(5):528-38
107. Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009;41(6):708-11
108. Hecht M, Lin L, Kushida CA, et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin- deficiency narcolepsy. Sleep 2003;26(7):809-10
109. Arii J, Kanbayashi T, Tanabe Y, et al. CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders. Neurology 2004;63(12):2440-2
110. Gerashchenko D, Murillo-Rodriguez E, Lin L, et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 2003;184(2):1010-16
111. Lin JS. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 2000;4(5):471-503
112. Steininger TL, Alam MN, Gong H, et al. Sleep-waking discharge of neurons in the posterior lateral hypothalamus of the albino rat. Brain Res 1999;840(1-2):138-47
113. Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003;38(5):715-30
114. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci USA 2001;98(17):9965-70
115. Kanbayashi T, Kodama T, Kondo H, et al. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep 2009;32(2):181-7
116. Nishino S, Sakurai E, Nevsimalova S, et al. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep 2009;32(2):175-80
117. Tedford CE, Edgar DM, Seidel WF, et al. Effects of a novel, selective, and potent histamine H3 receptor antagonist, GT-2332, on rat sleep/wakefulness and canine cataplexy [abstract]. Soc Neurosci 1999;25:1134
118. Lin JS, Sakai K, Vanni-Mercier G, et al. Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res 1990;523(2):325-30
119. Heuer H, Schafer MK, O'Donnell D, et al. Expression of thyrotropin-releasing hormone receptor 2 (TRH-R2) in the central nervous system of rats. J Comp Neurol 2000;428(2):319-36
120. Sharp T, Bennett GW, Marsden CA. Thyrotropin-releasing hormone analogues increase dopamine release from slices of rat brain. J Neurochem 1982;39:1763-6
121. Keller HH, Bartholini G, Pletscher A. Enhancement of cerebral noradrenaline turnover by thyrotropin-releasing hormone. Nature 1974;248:528-9
122. Vogel HP, Benkert O, Illig R, et al. Psychoendocrinological and therapeutic effects of TRH in depression. Acta Psychiatr Scand 1977;56(3):223-32
123. Bunevicius R, Matulevicius V. Short-lasting behavioural effects of thyrotropin-releasing hormone in depressed women: results of placebo-controlled study. Psychoneuroendocrinology 1993;18(5-6):445-9
124. Broberger C, McCormick DA. Excitatory effects of thyrotropin-releasing hormone in the thalamus. J Neurosci 2005;25(7):1664-73
125. Hara J, Gerashchenko D, Wisor JP, et al. Thyrotropin-releasing hormone increases behavioral arousal through modulation of hypocretin/orexin neurons. J Neurosci 2009;29(12):3705-14
126. Gonzalez JA, Horjales-Araujo E, Fugger L, et al. Stimulation of orexin/hypocretin neurones by thyrotropin-releasing hormone. J Physiol 2009;587(Pt 6):1179-86
127. Parmentier R, Kolbaev S, Klyuch BP, et al. Excitation of histaminergic tuberomamillary neurons by thyrotropin-releasing hormone. J Neurosci 2009;29(14):4471-83
128. Schomburg L, Turwitt S, Prescher G, et al. Human TRH-degrading ectoenzyme cDNA cloning, functional expression, genomic structure and chromosomal assignment. Eur J Biochem 1999;265(1):415-22
129. Xu YL, Reinscheid RK, Huitron-Resendiz S, et al. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 2004;43(4):487-97
130. Porrino LJ, Daunais JB, Rogers GA, et al. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol 2005;3(9):e299
131. Ehrman LA, Williams MT, Schaefer TL, et al. Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice. Genes Brain Behav 2006;5(7):540-51
132. Huang YS, Guilleminault C. Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. Pediatr Neurol 2009;41(1):9-16
133. Krogsgaard-Larsen P, Frolund B, Liljefors T, Ebert B. GABA(A) agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic. Biochem Pharmacol 2004;68(8):1573-80
134. Wisor JP, Pasumarthi RK, Gerashchenko D, et al. Gamma-hydroxybutyrate modifies behavior and GABAergic and catecholaminergic signaling systems in a narcoleptic mouse model Sleep 2009;32(Suppl):A35
135. Kastin AJ, Akerstrom V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. JPET 1999;289:219-23
136. Yoshida Y, Fujiki N, Maki RA, et al. Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats. Neurosci Lett 2003;346(3):182-6
137. Fujiki N, Ripley B, Yoshida Y, et al. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep 2003;6(8):953-9
138. Schatzberg SJ, Barrett J, Cutter Kl, et al. Case study: effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Intern Med 2004;18(4):586-8
139. Mieda M, Willie JT, Hara J, et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA 2004;101(13):4649-54
140. Ripley B, Fujiki N, Okura M, et al. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001;8(3):525-34
141. Hanson LR, Martinez PM, Taheri S, et al. Intranasal administration of hypocretin 1 (Orexin A) bypasses the blood-brain barrier & targets the brain: a new strategy for the treatment of narcolepsy. Drug Deliv Technol 2004;4(4):66-71
142. Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007;27(52):14239-47
143. Liu M, Thankachan S, Kaur S, et al. Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. Eur J Neurosci 2008;28(7):1382-93
144. Roitberg B, Urbaniak K, Emborg M. Cell transplantation for Parkinson's disease. Neurol Res 2004;26(4):355-62
145. Arias-Carrion O, Murillo-Rodriguez E, Xu M, et al. Transplant of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep 2004;27:1465-70
146. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27(3):469-74
147. Bjorklund A. Neurobiology. Better cells for brain repair. Nature 1993;362(6419):414-15
148. Asahi S, Egashira S, Matsuda M, et al. Structure-activity relationship stidies on the novel neuropeptide orexin. In: Fujii N, editor, The Japanese peptide society; 2000. p. 37-40
149. Darker JG, Porter RA, Eggleston DS, et al. Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorg Med Chem Lett 2001;11(5):737-40
150. Croston GE, Olsson R, Currier EA, et al. Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino) ethyl)isochroman-1-one (AC-7954). J Med Chem 2002;45(23):4950-3
151. Zaveri N. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci 2003;73(6):663-78
152. Saar K, Mazarati AM, Mahlapuu R, et al. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci USA 2002;99(10):7136-41
153. Lecendreux M, Maret S, Bassetti C, et al. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003;12(4):347-8
154. Dauvilliers Y, Carlander B, River F, et al. IVIG treatment in narcolepsy: report on two new cases. J Sleep Res 2004;13(Suppl 1):167
155. Zuberi SM, Mignot E, Ling L, MacArthur I. Variable response to intravenous immunoglobulin therapy in childhood necolepsy. J Sleep Res 2004;13(Suppl 1):828
156. Fronczek R, Verschuuren J, Lammers GJ. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol 2007;254(11):1607-8
157. Chen W, Black J, Call P, Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol 2005;58(3):489-90
158. Taheri S, Krempetz M, Jackson M, et al. Autoimmune basis of narcolepsy using western blot analysis of lateral hypothalamus protein extract with serum and cerebrospinal fluid (CSF). Sleep 2003;26(Suppl):A285
159. Aran A, Nevsimalova S, Plazzi G, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009;32(8):979-83
160. Mishima K, Fujiki N, Yoshida Y, et al. Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. Sleep 2008;31(8):1119-26
161. Kanbayashi T, Shimohata T, Nakashima I, et al. Symptomatic narcolepsy in MS and NMO patients; new neurochemical and immunological implications. Arch Neurol 2009. In press